![Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire](https://mms.businesswire.com/media/20171212006311/en/629578/5/3143937_120917_DSI_Logo_Portrait_4c_CMYK_Original_JPG.jpg)
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire
![Puma Biotechnology Stock Forecast: down to 0.000000000003 USD? - PBYI Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis Puma Biotechnology Stock Forecast: down to 0.000000000003 USD? - PBYI Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis](https://walletinvestorstorage.b-cdn.net/graphs/forecast/cc/pbyi-stock-stock-prediction-price-graph.png?version=1675512829)
Puma Biotechnology Stock Forecast: down to 0.000000000003 USD? - PBYI Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
![Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America](https://www.pint-pharma.com/images/st_metanic/blog/blog-2.png)